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Hypoxia and angiogenesis are important factors in breast cancer progression. Little is known of hypoxia and angiogenesis in lymph
node metastases of breast cancer. The aim of this study was to quantify hypoxia, by hypoxia-induced marker expression levels, and
angiogenesis, by endothelial cell proliferation, comparing primary breast tumours and axillary lymph node metastases. Tissue sections
of the primary tumour and a lymph node metastasis of 60 patients with breast cancer were immunohistochemically stained for the
hypoxia-markers carbonic anhydrase 9 (CA9), hypoxia-inducible factor-1a (Hif-1a) and DEC-1 and for CD34/Ki-67. Endothelial cell
proliferation fraction (ECP%) and tumour cell proliferation fraction (TCP%) were assessed. On haematoxylin–eosin stain, the growth
pattern and the presence of a fibrotic focus were assessed. Hypoxia-marker expression, ECP% and TCP% in primary tumours and in
lymph node metastases were correlated to each other and to clinico-pathological variables. Median ECP% and TCP% in primary
tumours and lymph node metastases were comparable (primary tumours: ECP%¼4.02, TCP%¼19.54; lymph node metastases:
ECP%¼5.47, TCP%¼21.26). ECP% correlated with TCP% (primary tumours: r¼0.63, Po0.001; lymph node metastases: r¼0.76,
Po0.001). CA9 and Hif-1a expression were correlated (primary tumours P¼0.005; lymph node metastases Po0.001). In primary
tumours, CA9 and Hif-1a expression were correlated with DEC-1 expression (P¼0.05), presence of a fibrotic focus (Po0.007) and
mixed/expansive growth pattern (Po0.001). Primary tumours and lymph node metastases with CA9 or Hif-1a expression had a
higher ECP% and TCP% (Po0.003); in primary tumours, mixed/expansive growth pattern and fibrotic focus were characterised by
higher ECP% (P¼0.03). Furthermore, between primary tumours and lymph node metastases a correlation was found for ECP%,
TCP%, CA9 and Hif-1a expression (ECP% r¼0.51, Po0.001; TCP r¼0.77, Po0.001; CA9 and Hif-1a Po0.001). Our data
demonstrate that the growth of breast cancer lymph node metastases is angiogenesis dependent and that angiogenesis and hypoxia
in the primary tumour predict angiogenesis and hypoxia in the lymph node metastases. Together with previous findings in breast
cancer liver metastases, which grow in 96% of cases angiogenesis independently, these data suggest that both the intrinsic growth
characteristics and angiogenic potential of breast cancer cells and the site-specific tumour microenvironment determine angiogenesis
and hypoxia in breast cancer.
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Breast cancer is the most frequent neoplasm in women and the
most frequent cause of death in women between 35 and 55 years of
age (Uzzan et al, 2004). Although loco-regional spread and
recurrence of the disease can be debilitating, metastasis to distant
organs is the leading cause of breast cancer-related death.
Traditional metastasis models of breast cancer include the regional
lymph node basin as the first station in the metastatic cascade
from where further haematogenous dissemination to distant
organs occurs. In these models, the process of metastasis occurs
in an orderly fashion from the primary tumour to the regional
lymph nodes prior to systemic dissemination (Nathanson, 2003).
Lymph node involvement indeed predicts the likelihood of survival
as well as the likelihood that distant haematogenous metastases
will develop (Donegan, 1992; Heimann and Hellman, 2000; Chang
et al, 2003; Subramaniam and Isaacs, 2005). Nevertheless, recent
data (reviewed by Pantel et al) have supported models in which
haematogenous dissemination in breast cancer can either occur
directly from the primary tumour or from metastases that develop
in the lymph nodes or in distant organs (Pantel and Brakenhoff,
2004).
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sLittle is known about the contribution of established lymph node
metastases to the formation of blood-borne, distant metastases. Guidi
et al (2000) demonstrated that the presence of vascular hotspots and
increased microvessel density in lymph node metastases of breast
cancer and not in the primary tumour were correlated with a worse
prognosis. Their results suggest that angiogenesis in the lymph node
metastases may contribute to disease progression and the haema-
togenous spread of tumour cells. Angiogenesis indeed plays an
essential role in several aspects of neoplastic invasion and
progression (Folkman, 1986). In breast cancer, angiogenesis in the
primary tumour has been found to predict relapse-free survival and
overall survival (Weidner et al, 1991; Horak et al, 1992; Fox et al,
1994; Gasparini et al, 1994, 1997; Linderholm et al, 2000).
Another important component of tumour progression, and a
driving force of angiogenesis, is hypoxia (Chia et al, 2001; Schindl
et al, 2002; Bos et al, 2003; Colpaert et al, 2003a; Dery et al, 2005).
Under hypoxic conditions, hypoxia-inducible factor-1a (Hif-1a)i s
stabilized and serves to propagate a cascade of pathways which
include angiogenesis, glycolysis, proliferation and alterations in
microenvironmental pH (carbonic anhydrase 9 (CA9)) (Semenza,
1999). Differentiated embryo-chondrocyte-expressed gene 1 (DEC-
1) or STRA13 is one of the transcription factors involved in cell
differentiation, proliferation and apoptosis that has been shown to
be Hif-1a regulated (Wykoff et al, 2000). The expression patterns
of CA9, Hif-1a and DEC-1 have been shown to correlate with each
other, with angiogenesis and with the expression of angiogenic
factors (Giatromanolaki et al, 2003; Chakrabarti et al, 2004; Currie
et al, 2004; Bos et al, 2005; Vleugel et al, 2005). The profound
changes in different pathways due to hypoxia facilitate tumour
progression and invasion and lead to resistance to chemo- and
radiotherapeutic interventions (Harris, 2002; Vaupel, 2004).
Although primary tumour growth in breast cancer is angiogen-
esis dependent, we previously showed that 96% of liver metastases
of breast cancer grow according to a nonangiogenic replacement
pattern, marked by replacement of the hepatocytes by tumour cells
without any desmoplastic reaction (Stessels et al, 2004). Thus,
breast cancer liver metastases grow by coopting the sinusoidal
vessels. Furthermore, 51% of breast cancer skin deposits grows
according to a less angiogenic infiltrative pattern with lower
microvessel density, endothelial cell proliferation fraction (ECP%)
and CA9 expression (Colpaert et al, 2003b). Thus, the growth
pattern and the degree of angiogenesis of breast cancer seems to be
influenced by the local site-specific tumour microenvironment.
Only limited and conflicting data on angiogenesis, and, to the best
of our knowledge, no data on hypoxia in lymph node metastases of
breast cancer are available (Arapandoni-Dadioti et al, 1999; Edel
et al, 2000; Guidi et al, 2000). It is also of note that recent systemic
therapy approaches to control cancer include inhibitors of the Hif
pathway (Chau et al, 2005; Joyce, 2005; Tan et al, 2005), yet nearly
all studies on Hif are on primary tumours and it is not known
whether activation of Hif in the primary tumour is reflected at
secondary sites. If hypoxia is caused by oxygen utilisation due to
the particular oncogene pathway that is activated, as well as poor
angiogenesis, it is possible that this will result in similar hypoxia at
distant sites, whereas differences in angiogenesis response in the
tissue, may result in substantial discrepancies.
Therefore, the aim of this study was to quantify hypoxia, by
hypoxia-induced marker expression levels, and angiogenesis, by
endothelial cell proliferation, comparing primary breast tumours
and axillary lymph node metastases.
MATERIALS AND METHODS
Patient selection
In all, 60 newly diagnosed breast cancer patients – treated at the
General Hospital St-Augustinus, Wilrijk, Belgium – with histo-
pathological-confirmed lymph node involvement at time of
diagnosis were included, after written informed consent. All
protocols were reviewed and approved by the ethical committee of
the General Hospital St-Augustinus. Metastases with complete
replacement of the lymph node parenchyma by tumour tissue were
not eligible. Furthermore, only patients that did not receive any
breast cancer-related treatment (hormonal, chemo- and/or radio-
therapy) prior to surgery were included in this study. Table 1
summarizes clinico-pathological data of the study population. Age,
histological type, estrogen and progesteron receptor status, p53
and Her2/neu oncoprotein status were recorded by review of
pathology files.
All haematoxylin–eosin (HE)-stained slides of the primary
tumour and of the lymph nodes were reviewed to select one
paraffin block of the primary tumour and one representative
paraffin block of a lymph node metastasis, that is with tumour/
normal tissue interface, for additional immunohistochemical
(IHC) stains. If more than one lymph node metastasis was suitable
for analyses, one lymph node metastasis was randomly chosen. In
15 cases, a paraffin block from a second lymph node metastasis
was also selected. In four cases, lymph node metastases were too
small to obtain enough slides for all the IHC stains planned, in one
case the primary tumour could not be retrieved. On the HE slides,
Table 1 Clinico-pathological data of patients included
Clinico-pathological data (N¼60)
Mean age (years) 59.2 (25.3–84.4)
T status
a
T1 17
T2 33
T3 5
T4 5
N status
a
N1 28
N2 19
N3 13
Histological type PT
Ductal 48
Lobular 10
Special type 2
Tumour grade PT
b
I1 8
II 25
III 17
ER status PT
Negative 17
Positive 43
PR status PT
Negative 27
Positive 33
p53 status PT
Negative 40
Positive 20
Her2/neu status PT
Negative 48
Positive 12
PT¼primary tumour; ER¼estrogen receptor; PR¼progesteron receptor.
aT and N
status were assigned according to the TNM classification of the American Joint
Committee on Cancer (Green et al, 2002).
bTumours were histologically graded
according to the Nottingham modification of the Bloom and Richardson histological
grading scheme (Bloom and Richardson, 1957; Elston, 1987).
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primary tumour were assessed as previously defined (Hasebe et al,
1998; Colpaert et al, 2001, 2003b). In the infiltrative growth
pattern, carcinoma cells infiltrate between pre-existing breast
parenchymal structures, without significant disturbance of the
breast architecture. In the expansive growth pattern, the tumour
forms a well-circumscribed nodule consisting of carcinoma cells
and desmoplastic connective tissue. Pre-existing breast parench-
ymal structures are not present inside the tumour but are pushed
aside by the expansively growing nodule. The growth pattern is
mixed infiltrative–expansive, when the tumour consists of a
central expansive nodule surrounded by carcinoma cells showing
an infiltrative growth pattern. A fibrotic focus is defined as a scar-
like area, consisting of fibroblasts and collagen fibres, that
occupies various percentages of the centre of an invasive ductal
carcinoma of the breast. The size of the lymph node metastases
was measured with a ruler.
Endothelial and tumour cell proliferation fraction (TCP%)
Figure 1 presents an overview of all histological and IHC stainings
used in this study. For the visualisation of proliferating endothelial
cells, a CD34/Ki67 double-stain procedure was performed on an
automated IHC staining system (DakoCytomation Autostainer;
DakoCytomation, Glostru ¨p, Denmark). This technique is used to
simultaneously stain endothelial cells (cytoplasmic CD34) and
proliferating cells (nuclear Ki-67). After rehydration of 5mm slides
through a graded alcohol series, antigen retrieval was performed
by heating the slides for 30min in sodium-citrate buffer using a
warm water bath at 981C. Endogenous peroxidase was quenched
for 10min with 3% hydrogen peroxide (VWR International,
Leuven, Belgium) and the anti-Ki-67 primary antibody (clone
MIB-1, DakoCytomation, diluted 1/150) was incubated for 30min
followed by 30min of the horseradish peroxidase-labelled polymer
and 10min of the DAB from the ChemMate Envisionþdetection
system (DakoCytomation). After rinsing for 3min in sodium-
citrate buffer, sections were incubated with a second primary
antibody directed against CD34 (clone Qbend 10, DakoCytoma-
tion, diluted 1/50) for 60min followed by 30min of alkaline
phosphatase-labelled polymer and 15min of fast red staining
solution from the ChemMate Envisionþdetection system (Dako-
Cytomation).
The fraction of proliferating endothelial cells (ECP%) and the
fraction of proliferating tumour cells (TCP%) were assessed at the
tumour/normal tissue interface, identified at low magnification
( 10 ocular and  10 objective). On a higher magnification ( 10
ocular and  40 objective) a total number of approximately 500
endothelial (¼CD34 positive) or tumour cells, respectively, were
evaluated on consecutive fields. ECP% and TCP% were calculated
according to the following formulas : ECP%¼(the number of
endothelial cells with Ki67-stained nuclei/total number of en-
dothelial cells evaluated) 100; TCP%¼(the number of tumour
cells with Ki67-stained nuclei/total number of tumour cells
evaluated) 100. For statistical analysis, ECP% and TCP% in the
primary tumour and in the lymph node metastases were also
dichotomised using the median as a cutoff.
Hypoxia
For the IHC evaluation of hypoxia, slides were stained for the
following antigens: CA9, DEC-1 and Hif-1a. CA9 and DEC-1 IHC
staining were automated using the DakoCytomation Autostainer
(DakoCytomation). Primary antibodies anti-CA9 (Rabbit poly-
clonal, NB 100-417A, Novus Biologicals, Littleton, CO, USA,
diluted 1/2000) and anti-DEC-1 (CW27 rabbit polyclonal, Kindly
provided by Professor Dr A Harris, diluted 1/1000) were incubated
for 60min at room temperature. Antibody binding was visualised
using the ChemMate Envisionþdetection system (DakoCytoma-
tion). Semiquantitative analysis of CA9 and DEC-1 expression was
carried out as described before (Chia et al, 2001; Chakrabarti et al,
2004). In brief, for CA9 a score of 0–3 for intensity of staining was
given (0: no staining, 1: weak staining, 2: moderate staining, 3:
strong staining). The percentage of immunostained tumour cells
was estimated. The product (intensity score the percentage of
immunoreactive tumour cells) yielded a final score of 0–300. For
statistical evaluation, any CA9 score above 0 was called positive.
For DEC-1, a 0–3 score was given based on intensity of nuclear
staining of tumour cells (0: no staining, 1: weak staining, 2:
moderate staining, 3: strong staining). For statistical analysis,
DEC-1 score 0–1 was called negative, DEC-1 score 2–3 was called
positive. The Hif-1a IHC staining was carried out manually,
slightly modifying the protocol as described by Bos et al (2001).
Briefly, slides were deparaffinised and rehydrated. After endogen-
ous peroxidase blocking in 3% hydrogen peroxide (VWR
International) and antigen retrieval using Target Retrieval Solution
(S1699, DakoCytomation) and warm water bath at 981C, the
Catalysed Signal Amplification system (DakoCytomation) was
used for Hif-1a staining according to the manufacturer’s instruc-
tions. Anti-Hif-1a primary antibody (Clone 54, BD Pharmingen,
Franklin Lake, NJ, USA; diluted 1/500) was incubated for 30min at
room temperature. For Hif-1a expression analysis, only cells with
completely and darkly stained nuclei were regarded as positive.
The fraction of Hif-1a-positive tumour cells was estimated. For
statistical analysis tumours or lymph node metastases with a Hif-
1a-positive tumour cell fraction 45% were considered positive,
else negative.
CA9, DEC-1 and Hif-1a analyses were carried out by GVdE and
were repeated by the same observer after 1 month. A high
reproducibility (k-value 40.95) was found.
Statistical analysis
Statistical analysis was performed with the SPSS 11.0 software
package. A P-value o0.05 was considered statistically significant.
Normality was tested with a Kolmogorov–Smirnov test assuming
normality of data if PX0.2. If continuous data (e.g. ECP% and
TCP%) were normally distributed, correlations were analysed with
Pearson’s correlation statistics, if not with Spearman’s correlation
statistics. In case of normal distribution in all subgroups, equality
of means was tested with a student T-test, if data were not
normally distributed, equality of medians was tested with a Mann–
Whitney U-test. For analysing correlations between categorical
variables (e.g. CA9, DEC-1 and Hif-1a expression, dichotomised
ECP% and TCP%, clinico-pathological variables) the w
2 test or –
when the assumptions of the w
2 test were not met – the Fisher’s
exact test, were used. A linear regression analysis with stepwise
forward procedure of the ECP% of the lymph node metastases was
performed including all angiogenesis, hypoxia and clinico-
pathological variables of both primary tumours and lymph node
metastases.
RESULTS
Angiogenesis and tumour cell proliferation
Median ECP% and TCP% in primary tumours and in lymph node
metastases were comparable (primary tumours: ECP%¼4.02,
TCP%¼19.54; lymph node metastases: ECP%¼5.47,
TCP%¼21.26; Wilcoxon’s signed-ranks test ECP% P¼0.911;
TCP% P¼0.566). Both in primary tumours and in lymph node
metastases, ECP% and TCP% were strongly correlated (Figure 2).
Furthermore, ECP% and TCP% in two different lymph node
metastases (N¼15) from the same patient showed a very strong
correlation (ECP%: r¼0.80, Po0.001; TCP%: r¼0.90, Po0.001).
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mixed or expansive growth pattern compared with primary
tumours with an infiltrative growth pattern (ECP% P¼0.03,
TCP% P¼0.08). Median ECP% or TCP% of the primary tumour
did not correlate with the presence of a fibrotic focus. No
correlation was found between ECP% or TCP% of the lymph node
metastases and the growth pattern or presence of a fibrotic focus in
the primary tumour. When ECP% and TCP% in the primary
tumours and in the lymph node metastases were dichotomised, a
high ECP% in the primary tumour was correlated with the
presence of a fibrotic focus (P¼0.05) and with an expansive or
mixed growth pattern (P¼0.05). Furthermore, a high ECP% in the
Figure 1 Overview of the histological and immunohistochemical stainings used, in a primary tumour (left: A, C and E) and in the corresponding lymph
node metastasis (right: B, D and F) with expression of hypoxia markers and high ECP%. A and B: HE staining showed the presence of a large fibrotic focus
(*) in the primary tumour. C and D: On CD34/Ki-67 IHC double-staining ECP% was high. Insets show Ki-67-positive (brown nucleus) endothelial cells (red
cytoplasm) (black arrows). E and F: Membranous CA9 staining of tumour cells in both the primary tumour and in the lymph node metastasis was
demonstrated. Insets show nuclear Hif-1a (upper inset) and DEC-1 (lower inset) expression in the same tumour region. ECP%: endothelial cell proliferation
fraction; HE: haematoxylin–eosin; CA9: carbonic anhydrase 9; Hif-1a: hypoxia-inducible factor-1a; DEC-1: differentiated embryo-chondrocyte-expressed
gene 1.
Angiogenesis and hypoxia in breast cancer lymph node metastases
GG Van den Eynden et al
1131
British Journal of Cancer (2005) 93(10), 1128–1136 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
slymph node metastases was correlated with an expansive or mixed
growth pattern in the primary tumour (P¼0.05).
Hypoxia
CA9, DEC-1 and Hif-1a were expressed in, respectively, 38.3, 76.7
and 46.7% of primary tumours. In lymph node metastases, 21.7,
66.7 and 26.7% were positive for, respectively, CA9, DEC-1 and
Hif-1a. In all, 42.4% of primary tumours did have a fibrotic focus
and 25.4, 23.7 and 50.0% of primary tumours had an infiltrative,
expansive or mixed growth pattern, respectively. Expressions of
CA9 and Hif-1a were correlated in primary tumours (Po0.001)
and in lymph node metastases (P¼0.005). A trend to a correlation
between DEC-1 and CA9 (P¼0.05) and between DEC-1 and Hif-1a
expression (P¼0.05) was found in primary tumours. In lymph
node metastases, no correlation between DEC-1 and CA9
(P¼0.74) or Hif-1a (P¼1.0) was found. Furthermore, when two
lymph node metastases from the same patient were compared, a
perfect correlation was found for CA9 expression (Po0.001). A
strong correlation was found for Hif-1a (Po0.001): in only one
case one lymph node metastasis expressed Hif-1a, while the other
did not. Figure 3 depicts boxplots comparing median ECP% and
TCP% in primary tumours (upper part) and lymph node
metastases (lower part) positive or negative for, respectively,
CA9, DEC-1 and Hif-1a. ECP% and TCP% are significantly higher
in primary tumours and lymph node metastases expressing CA9 or
Hif-1a. Furthermore, primary tumours with a fibrotic focus more
frequently expressed CA9 (P¼0.005) or Hif-1a (P¼0.007).
Similarly, more CA9 (Po0.001) and Hif-1a (Po0.001) expression
was demonstrated in primary tumours with a mixed or expansive
growth pattern, compared to primary tumours with an infiltrative
growth pattern. No significant correlation was found between the
growth pattern of the primary tumour or the presence of a fibrotic
focus in the primary tumour and DEC-1 expression in the primary
tumour or the expression of CA9, Hif-1a and DEC-1 in the lymph
node metastases.
Angiogenesis, hypoxia and clinico-pathological variables
In primary tumours, tumour grade was positively correlated with
ECP% (P¼0.002) and TCP% (Po0.001). Her2/neu status posi-
tively correlated with ECP% (Po0.001), TCP% (P¼0.004), CA9
(P¼0.001) and Hif-1a expression (P¼0.005). Estrogen receptor
status was negatively correlated with TCP% (P¼0.003) and CA9
(P¼0.04) and progesteron receptor status with ECP% (P¼0.005),
TCP% (P¼0.001), CA9 (Po0.001), Hif-1a (P¼0.003) and DEC-1
(P¼0.02). In lymph node metastases, comparable data were found
(data not shown).
Angiogenesis and hypoxia in lymph node metastases vs
primary tumours
A very good correlation was found between TCP% in primary
tumours and in lymph node metastases (r¼0.77, Po0.001) and
between ECP% in primary tumours and in lymph node metastases
(r¼0.51, Po0.001) (Figure 4). Furthermore, when dichotomised,
primary tumours with high ECP% or TCP% had lymph node
metastases with high ECP% or TCP%, respectively (ECP%
Po0.001; TCP% Po0.001). Table 2 shows the correlation between
primary tumours and lymph node metastases for CA9 and Hif-1a
expression. A very strong correlation was found both for CA9
(Po0.001) and Hif-1a (Po0.001). For DEC-1 no correlation was
found between expression in primary tumours and in lymph node
metastases (P¼0.45). Linear regression analysis revealed that
TCP% of the lymph node metastasis (b¼0.113, Po0.001), size of
the lymph node metastasis (b¼0.429, Po0.001) and CA9
expression of the lymph node metastasis (b¼4.088, P¼0.004)
were the most important determinants of ECP% of the lymph node
metastases.
DISCUSSION
In this study, angiogenesis and hypoxia in lymph node metastases
of 60 patients with breast cancer were investigated and compared
to angiogenesis and hypoxia in the primary tumour. Many
different histomorphological methods have been used to assess
tumour vascularity and angiogenesis. Endothelial cell proliferation
fraction has been described as being the preferred parameter for
quantification of angiogenesis (Vermeulen et al, 1996, 2002). In
contrast to other authors (Vartanian and Weidner, 1994), we
demonstrated a strong correlation between TCP% and ECP% both
in primary tumours and in lymph node metastases. This
correlation suggests that high tumour cell proliferation and
increased angiogenesis are linked. High tumour cell proliferation
involves increased oxygen consumption, leading to oxygen
deficiency and hypoxia-modulated gene expression, including
activation of vascular endothelial growth factor and CA9 gene
transcription by Hif-1a (Forsythe et al, 1996; Jiang et al, 1997;
Maxwell et al, 1997; Carmeliet et al, 1998). TCP% and ECP% are
indeed strongly correlated with CA9 and Hif-1a expression. More
integrative histological markers of hypoxia-induced stromal tissue
remodelling are the growth pattern of the primary tumour and the
presence of a fibrotic focus. We previously demonstrated in
primary tumours of node-negative breast cancer patients (Colpaert
et al, 2001) and in skin deposits of breast cancer (Colpaert et al,
2003b) that the presence of a fibrotic focus and an expansive
growth pattern are correlated with increased angiogenesis and
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Figure 2 Scatter plot showing a strong correlation between ECP% and TCP% in both primary tumours (left) and lymph node metastases (right). ECP%:
endothelial cell proliferation fraction; TCP%: tumour cell proliferation fraction; PT: primary tumour; LNM: lymph node metastasis.
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shypoxia. These results are confirmed in this lymph node-positive
study population. Furthermore, TCP%, ECP% and hypoxic
markers are also correlated with tumour grade and Her2/neu
status and inversely correlated with ER and PR status. Existing
breast cancer literature is not always straightforward on associa-
tions between clinico-pathological data and angiogenesis and
hypoxia. Some authors indeed find the same associations (Hansen
et al, 2000; Chia et al, 2001; Bos et al, 2003; Koukourakis et al,
2003; Giatromanolaki et al, 2004; Gruber et al, 2004), whereas
others do not (Fox et al, 1994; Costello et al, 1995; Aranda and
Laforga, 1996; Schindl et al, 2002; Blackwell et al, 2004).
Differences in study population and in the methodology of
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sangiogenesis quantification make comparison of the results
difficult.
The results of this study further suggest that hypoxia is equally
important for angiogenesis in primary tumours and lymph node of
breast cancer. New breast cancer metastasis models (reviewed in
Pantel and Brakenhoff, 2004) emphasise the role of early
haematogenous dissemination of tumour cells in breast cancer
progression. Nevertheless, since angiogenesis is an important
process in tumour progression and metastasis (Folkman, 1986),
angiogenesis in lymph node metastases might also contributes to
this dissemination. Guidi et al (2000) demonstrated that the
presence of vascular hotspots and increased microvessel density in
axillary lymph node metastases, but not in primary breast cancer,
was associated with poor outcome. Increased hypoxia-induced
angiogenesis in lymph node metastases might be an explanation
for the correlation between CA9 expression in the primary tumour
and prognosis, in patients with lymph node-positive breast cancer
(Chia et al, 2001). Furthermore, the angiogenic potential and
growth characteristics of the tumour cells in the primary tumour
seem to be preserved during the metastatic process. The clonal
theory of the origin of metastases indeed predicts this (Kerbel,
1990). Guidi et al (2000) and Edel et al (2000) did not find a
correlation between the microvessel density and number of
proliferating endothelial cells per mm
2 in primary tumours and
in lymph node metastases. In the largest series of 35 ductal breast
carcinomas, Arapandoni et al demonstrated a correlation between
the microvessel score of the primary tumour and the lymph node
metastasis, although microvessel score in lymph node metastases
was decreased. None of these studies measured hypoxia-marker
expression and since different measures were used to quantify
angiogenesis, these results are difficult to compare with ours.
Although angiogenic and hypoxic properties of the primary
tumour and the lymph node metastases seem to correlate, multiple
linear regression analysis withheld only size of the lymph node
metastasis, TCP% of the lymph node metastasis and CA9
expression in the lymph node metastasis as factors independently
determining the ECP% of the lymph node metastasis. Furthermore,
a substantial number of lymph node metastases corresponding to
primary tumours positive for CA9 or Hif-1a, did not express CA9
or Hif-1a. These data suggest that the local tumour microenviron-
ment and the interaction between the characteristics of the
metastatic tumour cells and their microenvironment are influen-
cing the angiogenic phenotype of the lymph node metastases.
Previous work on different growth patterns at different tumour
sites in breast cancer supports these findings. Skin deposits of
breast cancer grow according to three different patterns with
different angiogenic properties (Colpaert et al, 2003b). The
expansive growth pattern, with induction of a desmoplastic new
stroma, showed a high ECP%, a high microvessel density and a
high CA9 expression. In the infiltrative growth pattern much lower
values were found. Furthermore, the growth pattern of the skin
deposit correlated with the growth pattern of the primary tumour.
Breast cancer liver metastases, on the other hand, almost always
show a ‘replacement’ growth pattern (Stessels et al, 2004): breast
cancer cells replace hepatocytes at the tumour/liver interface with
conservation of the liver plate architecture and cooption of the
sinusoidal vasculature of the liver. Almost no hypoxia and no
angiogenic switch is seen. These observations in primary tumours,
skin deposits, lymph node metastases and liver metastases of
breast cancer suggest an important role for the local, organ-
specific microenvironment in determining angiogenesis and
hypoxia during breast cancer growth. The liver is, due to its
physiological function, a densely vascularised organ and can host
metastases that exploit this environment by replacing the
hepatocytes and coopting the vasculature. Breast parenchyma,
lymph nodes and skin on the other hand are less well vascularised
and therefore probably unable to meet the high metabolic
demands of a growing malignancy with the pre-existing vascu-
lature. This hypothesis is supported by findings in animal models.
Monsky et al (2002) described different angiogenic responses when
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Figure 4 Scatter plot representing the correlation between primary tumours and lymph node metastases for ECP% (left) and TCP% (right). A strong
correlation was found for both TCP% and ECP%. ECP%: endothelial cell proliferation fraction; TCP%: tumour cell proliferation fraction; PT: primary tumour;
LNM: lymph node metastasis.
Table 2 Correlation between hypoxia parameters in primary tumours and in lymph node metastases
CA9 Po0.001 Hif-1a Po0.001
LNM
CA9 negative CA9 positive Hif-1a negative Hif-1a positive
PT
CA9 negative 31 1 Hif-1a negative 26 1
CA9 positive 11 12 Hif-1a positive 13 15
(PT: primary tumour, LNM: lymph node metastasis, CA9: carbonic anhydrase 9, Hif-1a: hypoxia inducible factor-1a). CA9 and Hif-1a expression in primary tumours and in lymph
node metastases correlated (CA9 and Hif-1a Po0.001).
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san estrogen-dependent breast tumour line was implanted either
into the mammary gland fat pad or into the cranium. Differences
in angiogenic and hypoxic properties of different tumour sites
might have therapeutic consequences when treatment with
antiangiogenic therapy is considered.
In conclusion, this study demonstrated that growth of lymph
node metastases in breast cancer, in contrast to metastatic growth
in the liver, is angiogenesis dependent and that hypoxia is – at least
partially – the driving force for the angiogenesis. Furthermore, the
angiogenesis and hypoxia in the lymph node metastases are
predicted by the angiogenesis and hypoxia in the primary
tumours. These new data, in combination with previous findings,
suggest that both the properties of the tumour cells in the primary
tumour and the microenvironment of tumour growth in breast
cancer are important in determining the angiogenic and hypoxic
properties. In the case of the lymph nodes it may be that the
oncogene programme is the main driver for generating hypoxia
and induction of angiogenesis. Evidence for this is the strong
association between Her2/neu with Hif-1a. Variation in angiogen-
esis and hypoxia dependent on the metastatic site have important
implications for anti-Hif-1a and antiangiogenic therapies.
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